CR20220255A - Inhibidores de egfr - Google Patents

Inhibidores de egfr

Info

Publication number
CR20220255A
CR20220255A CR20220255A CR20220255A CR20220255A CR 20220255 A CR20220255 A CR 20220255A CR 20220255 A CR20220255 A CR 20220255A CR 20220255 A CR20220255 A CR 20220255A CR 20220255 A CR20220255 A CR 20220255A
Authority
CR
Costa Rica
Prior art keywords
compound
egfr inhibitors
formula
medicament
pharmaceutically acceptable
Prior art date
Application number
CR20220255A
Other languages
English (en)
Inventor
Antonio Ricci
Bernd Kuhn
Yvonne Alice Nagel
Georg Jaeschke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220255A publication Critical patent/CR20220255A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud proporciona un compuesto que tiene la Fórmula general (I) o una sal farmacéuticamente aceptable de este, composiciones que incluyen el compuesto y métodos de uso del compuesto. El compuesto de Fórmula (I) se puede usar como un medicamento.
CR20220255A 2019-12-20 2020-12-18 Inhibidores de egfr CR20220255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19218403 2019-12-20
PCT/EP2020/086914 WO2021123084A1 (en) 2019-12-20 2020-12-18 Egfr inhibitors

Publications (1)

Publication Number Publication Date
CR20220255A true CR20220255A (es) 2022-07-11

Family

ID=69411052

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220255A CR20220255A (es) 2019-12-20 2020-12-18 Inhibidores de egfr

Country Status (17)

Country Link
US (1) US20230034696A1 (es)
EP (1) EP4076664B1 (es)
JP (1) JP2023506809A (es)
KR (1) KR20220118426A (es)
CN (1) CN114867531B (es)
AR (1) AR120799A1 (es)
AU (1) AU2020405326A1 (es)
BR (1) BR112022011690A2 (es)
CA (1) CA3160534A1 (es)
CL (1) CL2022001353A1 (es)
CO (1) CO2022006965A2 (es)
CR (1) CR20220255A (es)
IL (1) IL292104A (es)
MX (1) MX2022007634A (es)
PE (1) PE20221768A1 (es)
TW (1) TW202136263A (es)
WO (1) WO2021123084A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
US10385019B2 (en) * 2015-06-30 2019-08-20 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
GB201519644D0 (en) * 2015-11-06 2015-12-23 Univ Southampton Therapy and pharmaceutical composition
WO2018075823A1 (en) * 2016-10-19 2018-04-26 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
TW201945357A (zh) * 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2019183523A1 (en) * 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)

Also Published As

Publication number Publication date
AU2020405326A1 (en) 2022-05-12
CN114867531B (zh) 2024-03-22
KR20220118426A (ko) 2022-08-25
WO2021123084A1 (en) 2021-06-24
IL292104A (en) 2022-06-01
CL2022001353A1 (es) 2023-02-17
EP4076664A1 (en) 2022-10-26
MX2022007634A (es) 2022-07-19
CA3160534A1 (en) 2021-06-24
JP2023506809A (ja) 2023-02-20
US20230034696A1 (en) 2023-02-02
CN114867531A (zh) 2022-08-05
TW202136263A (zh) 2021-10-01
CO2022006965A2 (es) 2022-06-10
PE20221768A1 (es) 2022-11-11
EP4076664B1 (en) 2023-08-30
EP4076664C0 (en) 2023-08-30
AR120799A1 (es) 2022-03-16
BR112022011690A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
JOP20220008A1 (ar) مثبطات parp1
GEP20237506B (en) Pcsk9 antagonist compounds
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
TN2017000374A1 (en) TGF-β INHIBITORS
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CR20220251A (es) Nuevos derivados de metilquinazolinona
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
MX2022002976A (es) Inhibidores selectivos de jak1.
EA202193015A1 (ru) Ингибиторы cdk
MX2022001004A (es) Inhibidores de enzimas.
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
WO2018039077A8 (en) Therapeutic compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same